AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

RegulatoryACI-7104Positive

AI Analysis

Summary

AC Immune received FDA Fast Track designation and IND clearance for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. The regulatory milestone enables the company to advance its development program with expedited FDA review.

Outcome Details

FDA Fast Track designation and IND clearance granted for anti-alpha-synuclein active immunotherapy

Importance:6/10

Sentiment:

0.75

FDAFast Track DesignationIND ClearanceImmunotherapyParkinson's DiseaseACI-7104

Related Companies

$ACTI.ST

Read the original article

Published by GlobeNewswire Clinical Studies on August 11, 2026 11:00 AM

Read Original